Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Encephalopathy Pipeline Drugs Market Report Overview
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Its symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness.
The Encephalopathy pipeline market research report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects.
Encephalopathy Pipeline Products Market Segmentation by Targets
The key targets in the Encephalopathy pipeline products market are Solute Carrier Family 2 Facilitated Glucose Transporter Member 1, Endothelin B Receptor, Estrogen Receptor, 5-Hydroxytryptamine Receptor 1A, Aldehyde Dehydrogenase Mitochondrial, Cannabinoid Receptor 2, Complement C1q Subcomponent, G Protein Coupled Receptor 55, Interleukin 2, and NACHT LRR And PYD Domains Containing Protein 3, among others. Solute Carrier Family 2 Facilitated Glucose Transporter Member 1 has the highest number of products in the Encephalopathy pipeline products market.
Encephalopathy Pipeline Products Market Analysis by Targets
For more target insights into the Encephalopathy pipeline products market, download a free report sample
Encephalopathy Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Encephalopathy pipeline products market are Endothelin B Receptor Agonist, Estrogen Receptor Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Aldehyde Dehydrogenase Mitochondrial Activator, Cannabinoid Receptor 2 Agonist, Complement C1q Subcomponent Inhibitor, G Protein Coupled Receptor 55 Antagonist, Interleukin 2 Inhibitor, and NACHT LRR And PYD Domains Containing Protein 3 Inhibitor, among others. Endothelin B Receptor Agonist Inhibitor leads the Encephalopathy pipeline products market in terms of MoA.
Encephalopathy Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Encephalopathy pipeline products market, download a free report sample
Encephalopathy Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Encephalopathy pipeline products market are intravenous, oral, intracoronary, parenteral, and subcutaneous. Intravenous leads the Encephalopathy pipeline products market in terms of RoA.
Encephalopathy Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Encephalopathy pipeline products market, download a free report sample
Encephalopathy Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Encephalopathy pipeline products market are small molecule, cell therapy, gene therapy, peptide, synthetic peptide, gene-modified cell therapy, monoclonal antibody, and protein. Small molecule leads the Encephalopathy pipeline products market in terms of molecule type.
Encephalopathy Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Encephalopathy pipeline products market, download a free report sample
Encephalopathy Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Encephalopathy pipeline products market are Mithra Pharmaceuticals SA, Pharmazz Inc, ANLBio Co Ltd, Argenica Therapeutics Ltd, Biom Therapeutics LLC, BrainRepair UG, DeckTherapeutics Inc, F. Hoffmann-La Roche Ltd, Gene Therapy Research Institution Co Ltd, and Hope Biosciences LLC. Mithra Pharmaceuticals SA is the leading company in the Encephalopathy pipeline products market.
Encephalopathy Pipeline Products Market Analysis by Companies
To know more about the leading players in the Encephalopathy pipeline products market, download a free report sample
Encephalopathy Pipeline Products Market Report Overview
| Key Targets | Solute Carrier Family 2 Facilitated Glucose Transporter Member 1, Endothelin B Receptor, Estrogen Receptor, 5-Hydroxytryptamine Receptor 1A, Aldehyde Dehydrogenase Mitochondrial, Cannabinoid Receptor 2, Complement C1q Subcomponent, G Protein Coupled Receptor 55, Interleukin 2, and NACHT LRR And PYD Domains Containing Protein 3 |
| Key Mechanisms of Action | Endothelin B Receptor Agonist, Estrogen Receptor Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Aldehyde Dehydrogenase Mitochondrial Activator, Cannabinoid Receptor 2 Agonist, Complement C1q Subcomponent Inhibitor, G Protein Coupled Receptor 55 Antagonist, Interleukin 2 Inhibitor, and NACHT LRR And PYD Domains Containing Protein 3 Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Intracoronary, Parenteral, and Subcutaneous |
| Key Molecule Type | Small Molecule, Cell Therapy, Gene Therapy, Peptide, Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody, and Protein |
| Leading Companies | Mithra Pharmaceuticals SA, Pharmazz Inc, ANLBio Co Ltd, Argenica Therapeutics Ltd, Biom Therapeutics LLC, BrainRepair UG, DeckTherapeutics Inc, F. Hoffmann-La Roche Ltd, Gene Therapy Research Institution Co Ltd, and Hope Biosciences LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Argenica Therapeutics Ltd
Biom Therapeutics LLC
BrainRepair UG
F. Hoffmann-La Roche Ltd
Gene Therapy Research Institution Co Ltd
Hope Biosciences LLC
Jazz Pharmaceuticals Plc
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Orphan Star Therapeutics LLC
Pfizer Inc
Pharmazz Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
Rohto Pharmaceutical Co Ltd
SL Bigen Co Ltd
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Encephalopathy pipeline products market?
The key targets in the Encephalopathy pipeline products market are Solute Carrier Family 2 Facilitated Glucose Transporter Member 1, Endothelin B Receptor, Estrogen Receptor, 5-Hydroxytryptamine Receptor 1A, Aldehyde Dehydrogenase Mitochondrial, Cannabinoid Receptor 2, Complement C1q Subcomponent, G Protein Coupled Receptor 55, Interleukin 2, and NACHT LRR And PYD Domains Containing Protein 3, among others.
-
What are the key mechanisms of action in the Encephalopathy pipeline products market?
The key mechanisms of action in the Encephalopathy pipeline products market are Endothelin B Receptor Agonist, Estrogen Receptor Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, Aldehyde Dehydrogenase Mitochondrial Activator, Cannabinoid Receptor 2 Agonist, Complement C1q Subcomponent Inhibitor, G Protein Coupled Receptor 55 Antagonist, Interleukin 2 Inhibitor, and NACHT LRR And PYD Domains Containing Protein 3 Inhibitor, among others.
-
What are the key routes of administration in the Encephalopathy pipeline products market?
The key routes of administration in the Encephalopathy pipeline products market are intravenous, oral, intracoronary, parenteral, and subcutaneous.
-
What are the key molecule types in the Encephalopathy pipeline products market?
The key molecule types in the Encephalopathy pipeline products market are small molecule, cell therapy, gene therapy, peptide, synthetic peptide, gene-modified cell therapy, monoclonal antibody, and protein.
-
Which are the leading companies in the Encephalopathy pipeline products market?
Some of the leading companies in the Encephalopathy pipeline products market are Mithra Pharmaceuticals SA, Pharmazz Inc, ANLBio Co Ltd, Argenica Therapeutics Ltd, Biom Therapeutics LLC, BrainRepair UG, DeckTherapeutics Inc, F. Hoffmann-La Roche Ltd, Gene Therapy Research Institution Co Ltd, and Hope Biosciences LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Central Nervous System reports